vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and BRAND HOUSE COLLECTIVE, INC. (TBHC). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $103.5M, roughly 1.3× BRAND HOUSE COLLECTIVE, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -3.6%, a 39.1% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -9.6%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-26.8M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -21.0%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Soho House is an international private members’ club with a focus on the media, arts and fashion industries.
ADMA vs TBHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $103.5M |
| Net Profit | $49.4M | $-3.7M |
| Gross Margin | 63.8% | 20.4% |
| Operating Margin | 45.1% | -1.9% |
| Net Margin | 35.5% | -3.6% |
| Revenue YoY | 18.4% | -9.6% |
| Net Profit YoY | -55.9% | 51.8% |
| EPS (diluted) | $0.20 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $103.5M | ||
| Q3 25 | $134.2M | $75.8M | ||
| Q2 25 | $122.0M | $81.5M | ||
| Q1 25 | $114.8M | $148.9M | ||
| Q4 24 | $117.5M | $114.4M | ||
| Q3 24 | $119.8M | $86.3M | ||
| Q2 24 | $107.2M | $91.8M | ||
| Q1 24 | $81.9M | $165.9M |
| Q4 25 | $49.4M | $-3.7M | ||
| Q3 25 | $36.4M | $-20.2M | ||
| Q2 25 | $34.2M | $-11.8M | ||
| Q1 25 | $26.9M | $7.9M | ||
| Q4 24 | $111.9M | $-7.7M | ||
| Q3 24 | $35.9M | $-14.5M | ||
| Q2 24 | $32.1M | $-8.8M | ||
| Q1 24 | $17.8M | $10.1M |
| Q4 25 | 63.8% | 20.4% | ||
| Q3 25 | 56.3% | 16.3% | ||
| Q2 25 | 55.1% | 24.9% | ||
| Q1 25 | 53.2% | 30.3% | ||
| Q4 24 | 53.9% | 28.1% | ||
| Q3 24 | 49.8% | 20.5% | ||
| Q2 24 | 53.6% | 29.5% | ||
| Q1 24 | 47.8% | 32.0% |
| Q4 25 | 45.1% | -1.9% | ||
| Q3 25 | 38.0% | -24.7% | ||
| Q2 25 | 35.1% | -12.9% | ||
| Q1 25 | 30.4% | 6.2% | ||
| Q4 24 | 32.6% | -2.1% | ||
| Q3 24 | 33.1% | -15.4% | ||
| Q2 24 | 36.6% | -8.2% | ||
| Q1 24 | 26.7% | 6.4% |
| Q4 25 | 35.5% | -3.6% | ||
| Q3 25 | 27.1% | -26.6% | ||
| Q2 25 | 28.1% | -14.5% | ||
| Q1 25 | 23.4% | 5.3% | ||
| Q4 24 | 95.2% | -6.7% | ||
| Q3 24 | 30.0% | -16.8% | ||
| Q2 24 | 29.9% | -9.6% | ||
| Q1 24 | 21.7% | 6.1% |
| Q4 25 | $0.20 | $-0.16 | ||
| Q3 25 | $0.15 | $-0.90 | ||
| Q2 25 | $0.14 | $-0.54 | ||
| Q1 25 | $0.11 | $0.61 | ||
| Q4 24 | $0.45 | $-0.59 | ||
| Q3 24 | $0.15 | $-1.11 | ||
| Q2 24 | $0.13 | $-0.68 | ||
| Q1 24 | $0.08 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $6.5M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $-44.0M |
| Total Assets | $624.2M | $229.2M |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $6.5M | ||
| Q3 25 | $61.4M | $3.6M | ||
| Q2 25 | $90.3M | $3.5M | ||
| Q1 25 | $71.6M | $3.8M | ||
| Q4 24 | $103.1M | $6.8M | ||
| Q3 24 | $86.7M | $4.5M | ||
| Q2 24 | $88.2M | $3.8M | ||
| Q1 24 | $45.3M | $3.8M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.0M | ||
| Q4 24 | $72.3M | $85.8M | ||
| Q3 24 | — | $61.4M | ||
| Q2 24 | — | $47.5M | ||
| Q1 24 | — | $34.0M |
| Q4 25 | $477.3M | $-44.0M | ||
| Q3 25 | $431.2M | $-35.2M | ||
| Q2 25 | $398.3M | $-16.2M | ||
| Q1 25 | $373.4M | $-19.0M | ||
| Q4 24 | $349.0M | $-27.1M | ||
| Q3 24 | $231.9M | $-19.7M | ||
| Q2 24 | $188.3M | $-5.5M | ||
| Q1 24 | $153.7M | $3.1M |
| Q4 25 | $624.2M | $229.2M | ||
| Q3 25 | $568.7M | $221.9M | ||
| Q2 25 | $558.4M | $225.4M | ||
| Q1 25 | $510.6M | $242.2M | ||
| Q4 24 | $488.7M | $279.8M | ||
| Q3 24 | $390.6M | $266.2M | ||
| Q2 24 | $376.4M | $242.6M | ||
| Q1 24 | $350.9M | $250.6M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-25.9M |
| Free Cash FlowOCF − Capex | $34.6M | $-26.8M |
| FCF MarginFCF / Revenue | 24.8% | -25.9% |
| Capex IntensityCapex / Revenue | 0.8% | 0.9% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-18.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-25.9M | ||
| Q3 25 | $13.3M | $-7.0M | ||
| Q2 25 | $21.1M | $-3.1M | ||
| Q1 25 | $-19.7M | $19.8M | ||
| Q4 24 | $50.2M | $-12.6M | ||
| Q3 24 | $25.0M | $-12.7M | ||
| Q2 24 | $45.6M | $-13.7M | ||
| Q1 24 | $-2.2M | $28.2M |
| Q4 25 | $34.6M | $-26.8M | ||
| Q3 25 | $-1.1M | $-7.4M | ||
| Q2 25 | $18.7M | $-3.6M | ||
| Q1 25 | $-24.4M | $19.0M | ||
| Q4 24 | $47.5M | $-13.1M | ||
| Q3 24 | $24.0M | $-13.2M | ||
| Q2 24 | $43.6M | $-14.4M | ||
| Q1 24 | $-4.6M | $26.7M |
| Q4 25 | 24.8% | -25.9% | ||
| Q3 25 | -0.8% | -9.8% | ||
| Q2 25 | 15.3% | -4.5% | ||
| Q1 25 | -21.2% | 12.8% | ||
| Q4 24 | 40.4% | -11.5% | ||
| Q3 24 | 20.0% | -15.2% | ||
| Q2 24 | 40.7% | -15.7% | ||
| Q1 24 | -5.6% | 16.1% |
| Q4 25 | 0.8% | 0.9% | ||
| Q3 25 | 10.7% | 0.6% | ||
| Q2 25 | 2.0% | 0.7% | ||
| Q1 25 | 4.1% | 0.5% | ||
| Q4 24 | 2.3% | 0.4% | ||
| Q3 24 | 0.9% | 0.5% | ||
| Q2 24 | 1.9% | 0.8% | ||
| Q1 24 | 2.9% | 0.9% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | 2.51× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | 2.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
TBHC
Segment breakdown not available.
